- Seeks patent on new therapy for drug that employs concentrations of THC
- Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss
- IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product
India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://cnw.fm/UhYF1). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron damage.
This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.
Read the full article